IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

PLoS Pathogens

Volumn 4, Issue 3, 2008, Pages

  Sommereyns, Caroline ^a   Paul, Sophie ^a   Staeheli, Peter ^b   Michiels, Thomas ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; INTERLEUKIN 28 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; LAMBDA INTERFERON; CYTOKINE; INTERFERON LAMBDA PROTEIN, MOUSE; INTERFERON-LAMBDA PROTEIN, MOUSE; MESSENGER RNA; VIRUS RNA;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL SPECIFICITY; CELL TYPE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ELECTROPORATION; EPITHELIUM CELL; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; INTESTINE; KIDNEY; LIVER; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA VIRUS; RNA VIRUS INFECTION; SPLEEN; STOMACH; TISSUE SPECIFICITY; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CONGENIC STRAIN; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; VIROLOGY;

RNA VIRUSES;

ANIMALS; BRAIN; CYTOKINES; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, VIRAL; KIDNEY; LIVER; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; ORGAN SPECIFICITY; RNA VIRUSES; RNA, MESSENGER; RNA, VIRAL;

EID: 42949160129     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000017     Document Type: Article

References (64)

1. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-267.
2. Goodbourn S, Didcock L, Randall RE (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81: 2341-2364.
3. Zwarthoff EC, Mooren AT, Trapman J (1985) Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res 13: 791-804.
4. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202: 8-32.
5. van Pesch V, Lanaya H, Renauld JC, Michiels T (2004) Characterization of the murine alpha interferon gene family. J Virol 78: 8219-8228.
6. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, et al. (2001) Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276: 39765-39771.
7. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ (2004) Characterization of the type I interferon locus and identification of novel genes. Genomics 84: 331-345.
8. Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y (2001) Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 12: 337-348.
9. Sommereyns C, Michiels T (2006) N-glycosylation of murine IFN-beta in a putative receptor-binding region. J Interferon Cytokine Res 26: 406-413.
10. van Pesch V, Michiels T (2003) Characterization of interferon-alpha 13, a novel constitutive murine interferon-alpha subtype. J Biol Chem 278: 46321-46328.
11. Huang J, Smirnov SV, Lewis-Antes A, Balan M, Li W, et al. (2007) Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A 104: 9822-9827.
12. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, et al. (2006) Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 26: 1888-1897.
13. Jaks E, Gavutis M, Uze G, Martal J, Piehler J (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366: 525-539.
14. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
15. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
16. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, et al. (2006) Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66: 4468-4477.
17. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501-4509.
18. Uze G, Monneron D (2007) IL-28 and IL-29: newcomers to the interferon family. Biochimie 89: 729-734.
19. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, et al. (2007) Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282: 7576-7581.
20. Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, et al. (2005) Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 79: 9608-9617.
21. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, et al. (2005) Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23: 465-478.
22. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, et al. (1995) Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 270: 21606-21611.
23. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC (2003) Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 370: 391-396.
24. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al. (2005) IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289: G960-968.
25. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, et al. (2004) Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279: 32269-32274.
26. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, et al. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81: 7749-7758.
27. Platanias LC, Fish EN (1999) Signaling pathways activated by interferons. Exp Hematol 27: 1583-1592.
28. Ank N, West H, Paludan SR (2006) IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 26: 373-379.
29. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL (2005) Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86: 1589-1596.
30. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176: 7686-7694.
31. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, et al. (2007) Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 8: 13-20.
32. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, et al. (2007) Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 8: 254-261.
33. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, et al. (2006) Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci U S A 103: 7835-7840.
34. Matthews AE, Weiss SR, Paterson Y (2002) Murine hepatitis virus - a model for virus-induced CNS demyelination. J Neurovirol 8: 76-85.
35. Plagemann PG, Moennig V (1992) Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses. Adv Virus Res 41: 99-192.
36. Stueckemann JA, Holth M, Swart WJ, Kowalchyk K, Smith MS, et al. (1982) Replication of lactate dehydrogenase-elevating virus in macrophages. 2. Mechanism of persistent infection in mice and cell culture. J Gen Virol 59: 263-272.
37. Anderson GW, Palmer GA, Rowland RR, Even C, Plagemann PG (1995) Lactate dehydrogenase-elevating virus entry into the central nervous system and replication in anterior horn neurons. J Gen Virol 76 (Pt 3): 581-592.
38. Dubuy H, Baron S, Uhlendorf C, Johnson ML (1973) Role of interferon in murine lactic dehydrogenase virus infection, in vivo and in vitro. Infect Immun 8: 977-984.
39. Blakqori G, Delhaye S, Habjan M, Blair CD, Sanchez-Vargas I, et al. (2007) La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol 81: 4991-4999.
40. Brahic M, Bureau JF, Michiels T (2005) The genetics of the persistent infection and demyelinating disease caused by Theiler's virus. Annu Rev Microbiol 59: 279-298.
41. Roos RP (2002) Pathogenesis of Theiler's Murine Encephalomyelitis Virus-induced Disease. In: Semler BL, Wimmer E, eds. Molecular Biology of Picornaviruses ASM Press. pp 427-435.
42. Li S, Zhang X, Xia X, Zhou L, Breau R, et al. (2001) Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 8: 400-407.
43. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, et al. (2004) Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34: 796-805.
44. Jouanguy E, Zhang SY, Chapgier A, Sancho-Shimizu V, Puel A, et al. (2007) Human primary immunodeficiencies of type I interferons. Biochimie 89: 878-883.
45. Paul S, Ricour C, Sommereyns C, Sorgeloos F, Michiels T (2007) Type I interferon response in the central nervous system. Biochimie 89: 770-778.
46. Adorini L (2004) Immunotherapeutic approaches in multiple sclerosis. J Neurol Sci 223: 13-24.
47. Neuhaus O, Archelos JJ, Hartung HP (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24: 131-138.
48. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, et al. (2003) IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 170: 4776-4784.
49. Group TI-bMSS (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43: 655-661.
50. Dieperink E, Willenbring M, Ho SB (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 157: 867-876.
51. Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19: 105-123.
52. Levraud JP, Boudinot P, Colin I, Benmansour A, Peyrieras N, et al. (2007) Identification of the zebrafish IFN receptor: implications for the origin of the vertebrate IFN system. J Immunol 178: 4385-4394.
53. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, et al. (2006) Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12: 1023-1026.
54. Horisberger MA, Staeheli P, Haller O (1983) Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc Natl Acad Sci U S A 80: 1910-1914.
55. Koerner I, Kochs G, Kalinke U, Weiss S, Staeheli P (2007) Protective role of beta interferon in host defense against influenza A virus. J Virol 81: 2025-2030.
56. Blakqori G, Weber F (2005) Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or lacking the nonstructural protein NSs. J Virol 79: 10420-10428.
57. Godfraind C, Holmes KV, Coutelier JP (1995) Thymus involution induced by mouse hepatitis virus A59 in BALB/c mice. J Virol 69: 6541-6547.
58. Coutelier JP, Van Snick J (1985) Isotypically restricted activation of B lymphocytes by lactic dehydrogenase virus. Eur J Immunol 15: 250-255.
59. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
60. Paul S, Michiels T (2006) Cardiovirus leader proteins are functionally interchangeable and have evolved to adapt to virus replication fitness. J Gen Virol 87: 1237-1246.
61. Kunkel TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A 82: 488-492.
62. Vandermeulen G, Staes E, Vanderhaeghen ML, Bureau MF, Scherman D, et al. (2007) Optimisation of intradermal DNA electrotransfer for immunisation. Journal of Controlled Release;doi:10.1016/j.jconrel.2007.08.010.
63. DeWever J, Frérart F, Bouzin C, Baudelet C, Ansiaux R, et al. (2007) Caveolin-1 is critical for the maturation of tumor blood vessels through the regulation of both endothelial tube formation and mural cell recruitment. Am J Pathol 171: 1619-1628.
64. Meier E, Fah J, Grob MS, End R, Staeheli P, et al. (1988) A family of interferon-induced Mx-related mRNAs encodes cytoplasmic and nuclear proteins in rat cells. J Virol 62: 2386-2393.